Is Fragment 176-191 the same as AOD-9604?

No. AOD-9604 is a modified analogue of Fragment 176-191 — it adds a tyrosine residue intended to improve stability. They derive from the same C-terminal region of growth hormone and are often confused, but they are distinct molecules.

What part of growth hormone is Fragment 176-191?

It corresponds to amino acids 176 through 191 at the C-terminus of the 191-amino-acid human growth hormone sequence — the region preclinical work associated with growth hormone's effect on fat metabolism.

Is Fragment 176-191 FDA-approved?

No. Fragment 176-191 is not approved by the FDA or any major regulatory agency. It is handled as a research compound and is not authorised for human medical use.

Why is it dosed in micrograms rather than milligrams?

Reference protocols cite small per-administration amounts because the peptide has a short circulating half-life. Vials are usually labelled in milligrams; the calculator converts a milligram or microgram target into insulin-syringe units for a given reconstitution.

How long does a reconstituted vial last?

Reconstituted research peptides of this class are generally regarded as usable for roughly two to four weeks when stored refrigerated at 2–8 °C and protected from light. Specific stability data for Fragment 176-191 in controlled conditions is limited.

Fragment 176-191 Calculator

Fragment 176-191 (also known as HGH Frag 176-191) reconstitution and dosage reference — calculate vial concentration, BAC water volume, and exact syringe units below.

Also known as: HGH Frag 176-191, AOD fragment, Lipolytic fragment

Immune

Key takeaways

At the reference preset of a 5mg Fragment 176-191 vial reconstituted with 2 mL of bacteriostatic water, a 0.5mg dose measures 20 units on a U-100 insulin syringe.

Fragment 176-191 is a synthetic peptide corresponding to amino acids 176 through 191 at the C-terminus of the 191-residue human growth hormone (HGH) molecule.

Concentration: 2.5 mg/mL
Draw volume: 0.2 mL
Units (U-100): 20
Doses per vial: ≈ 10
Reference preset: 5mg · 2mL · 0.5mg

U-100 scale · draw to 20 units

Reference values from the default preset — adjust the calculator below for your vial.

Default: 5mg / 2mL / 0.5mgAdjust inputs to match your vial

About

What is Fragment 176-191?

Fragment 176-191 is a synthetic peptide corresponding to amino acids 176 through 191 at the C-terminus of the 191-residue human growth hormone (HGH) molecule. This region was identified in preclinical work as the part of the growth hormone sequence associated with its effect on fat metabolism (lipolysis). The interest in the isolated fragment is that, in animal models, it appeared to influence fat metabolism without the effects on blood glucose, insulin sensitivity, or IGF-1 that accompany full-length growth hormone. Fragment 176-191 is closely related to AOD-9604, a modified analogue developed as a pharmaceutical candidate, and the two are frequently confused. Fragment 176-191 is not approved by the FDA or any major regulatory agency and is handled as a research compound. Published human evidence for the lipolytic activity reported in early animal studies is limited and has not been consistently replicated in controlled clinical trials.

Common vial sizes

2 mg	lyophilized powder
5 mg	lyophilized powder
10 mg	lyophilized powder

Reference dose ranges

0.25 mg	≈ 10 U-100 units (at 5mg / 2mL)
0.5 mg	≈ 20 U-100 units (at 5mg / 2mL)
1 mg	≈ 40 U-100 units (at 5mg / 2mL)

Reconstitution

How it's typically prepared

Fragment 176-191 ships as a lyophilized powder. Reconstitute with bacteriostatic water by injecting the diluent slowly down the inner wall of the vial and swirling gently rather than shaking, since the peptide bond is fragile. Store the reconstituted solution refrigerated at 2–8 °C and protected from light; reconstituted research peptides of this class are generally regarded as usable for two to four weeks. A 5 mg vial reconstituted with 2 mL of bacteriostatic water yields a 2.5 mg/mL concentration, so a 0.5 mg reference dose corresponds to 0.2 mL — 20 units on a U-100 insulin syringe.

Dosage

How Fragment 176-191 is described in research literature

Reference protocols in the research literature most commonly cite Fragment 176-191 in microgram-to-low-milligram amounts per administration, sometimes split across the day, reflecting the peptide's short circulating half-life. Because the compound is investigational and unapproved, there is no established clinical dose, and the figures that circulate are derived from animal studies and anecdotal research reports rather than from controlled human trials. The calculator above renders the reconstitution math for whatever vial size, diluent volume, and target amount are entered; the numbers are an educational reference, not a dosing recommendation.

Fragment 176-191 is often grouped with AOD-9604 because both derive from the same C-terminal region of growth hormone. AOD-9604 was advanced into human obesity trials by Metabolic Pharmaceuticals; the later-phase results did not demonstrate a statistically significant fat-reduction benefit over placebo, which is an important caveat for anyone evaluating the unmodified fragment. The two molecules are related but not identical: AOD-9604 carries an added tyrosine modification intended to improve stability. Both remain outside approved medical use.

Chart

Fragment 176-191 reconstitution reference

Concentration and U-100 insulin-syringe volume for a 0.5 mg reference amount at common vial-and-diluent combinations. Use it as a quick cross-check against the calculator above.

2 mg in 1 mL	2 mg/mL · 0.5 mg = 0.25 mL · 25 units
5 mg in 2 mL	2.5 mg/mL · 0.5 mg = 0.2 mL · 20 units
5 mg in 1 mL	5 mg/mL · 0.5 mg = 0.1 mL · 10 units
10 mg in 2 mL	5 mg/mL · 0.5 mg = 0.1 mL · 10 units

FAQ

Frequently asked questions

Is Fragment 176-191 the same as AOD-9604?: No. AOD-9604 is a modified analogue of Fragment 176-191 — it adds a tyrosine residue intended to improve stability. They derive from the same C-terminal region of growth hormone and are often confused, but they are distinct molecules.
What part of growth hormone is Fragment 176-191?: It corresponds to amino acids 176 through 191 at the C-terminus of the 191-amino-acid human growth hormone sequence — the region preclinical work associated with growth hormone's effect on fat metabolism.
Is Fragment 176-191 FDA-approved?: No. Fragment 176-191 is not approved by the FDA or any major regulatory agency. It is handled as a research compound and is not authorised for human medical use.
Why is it dosed in micrograms rather than milligrams?: Reference protocols cite small per-administration amounts because the peptide has a short circulating half-life. Vials are usually labelled in milligrams; the calculator converts a milligram or microgram target into insulin-syringe units for a given reconstitution.
How long does a reconstituted vial last?: Reconstituted research peptides of this class are generally regarded as usable for roughly two to four weeks when stored refrigerated at 2–8 °C and protected from light. Specific stability data for Fragment 176-191 in controlled conditions is limited.

Sources

References

AOD-9604 — dosage calculator, reconstitution chart, and sources.
Thymosin Alpha-1 — dosage calculator, reconstitution chart, and sources.
HGH (Somatropin) — IU dosing reference and reconstitution chart.

Notice

PeptideDose is an educational reference. It is not medical advice and does not replace consultation with a licensed healthcare provider. Doses shown in presets are derived from published protocols and product labels — they are not personal recommendations.